-+ 0.00%
-+ 0.00%
-+ 0.00%

Valerio Therapeutics signs deal to buy Etherna Immunotherapies for €30 million enterprise value

PUBT·08/24/2026 06:00:40
Listen to the news
Valerio Therapeutics signs deal to buy Etherna Immunotherapies for €30 million enterprise value
  • Valerio Therapeutics agreed to acquire Etherna Immunotherapies in a deal valuing Etherna at EUR 30 million enterprise value.
  • Consideration includes cash funded by a EUR 40.25 million PIPE, with remaining payment in Valerio shares via in-kind Etherna share contributions.
  • Valerio issued 68,220,333 new shares at EUR 0.59 each; settlement-delivery is expected Aug. 26, 2026.
  • Shareholder approval for the in-kind contribution leg is targeted for around Oct. 6, 2026, backed by undertakings exceeding 70%.
  • Transaction adds Etherna’s mRNA and LNP platforms and GMP manufacturing, supporting Valerio’s push into targeted RNA delivery beyond the liver.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260823746971) on August 24, 2026, and is solely responsible for the information contained therein.